InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-21 | 2026-04-23 | Bonita David P | Director | Purchase | 2.82M | $4.44 | $12.50M | 11.81M | View ↗ |
No annual data found.
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
Prelude Therapeutics prices $90M equity offering
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer